Eckert & Ziegler Strahlen- und Medizintechnik AG / Preliminary Results
18.02.2010 11:28
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Berlin, 18 February 2010 - According to preliminary results (unaudited),
Berlin-based Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN
DE0005659700), a specialist for isotope technology in medicine, science and
industry, achieved sales growth of 42% to EUR 102 million (EUR 72 million)
for the fiscal year 2009. The same period saw an almost threefold increase
in the annual net profit from just under EUR 5 million to round EUR 14
million, or roughly EUR 3.58 per share. Note that the figures for 2009
include approximately EUR 6.2 million in positive special effects for
accrual closeouts and extraordinary legal fees associated with the takeover
bid for International Brachytherapy S.A (IBt) launched at the end of the
year. Excluding special effects, the annual net profit more than doubled
from EUR 3.4 million to EUR 7.4 million, or roughly EUR 1.95 per share,
taking into account also the capital increases. Liquid assets rose by EUR
36 million from EUR 7 million to EUR 43 million. Of the increase, EUR 21
million were assets raised in the last capital increase that had not yet
been invested as of the balance sheet date. Even more positive was the
contribution from the operating cash flow, which almost tripled compared to
the previous year's value to EUR 23 million.
---------------------------------------------------------------------------
Information and Explaination of the Issuer to this News:
The largest growth component was contributed by the Therapy segment. Sales
rose by 10% to EUR 30 million. Following losses in the previous year due to
restructuring measures, the revitalized segment came back to post
substantial profits. In addition to the long-term improved financial
performance, increased sales, in particular of Afterloaders in Eastern
Europe, as well as the Russian joint venture resonated positively. These
developments, coupled with re-entry into the American market, have
generated exceptional prospects for future growth.
The Industry segment generated the highest sales growth and the largest
absolute contribution to earnings. Sales rose by 73% to EUR 52 million,
while the annual net profit rose by 26% to EUR 5.3 million. The factors
driving growth were the consolidation of former competitor Nuclitec as well
as continued increases in sales of oil well logging sources.
With a sales increase of 31% to EUR 20 million, the Radiopharmaceuticals
segment posted a profit for the first time. This segment, too, profited
from the Nuclitec acquisition, which included the Auriga division.
All figures are provisional pending the final audit and financial
statements by the supervisory board.
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, D-13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, Fax -112
E-Mail: karolin.riehle@ezag.de, www.ezag.com
18.02.2010 11:28 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Medienarchiv at |[![CDATA[|[a href="http://www.dgap-medientreff.de"|]www.dgap-medientreff.de|[/a|]]]|] and |[![CDATA[|[a href="http://www.dgap.de"|]www.dgap.de|[/a|]]]|]
---------------------------------------------------------------------------
Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Deutschland
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700, DE000A0L1L69
WKN: 565970, A0L1L6
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, München, Düsseldorf, Hamburg
End of News DGAP News-Service
---------------------------------------------------------------------------
DGAP-Adhoc: Eckert & Ziegler: Sales, Profits and Cash Flow at Record Levels
| Source: EQS Group AG